

Antimicrobial resistance profiles of *E. coli* isolated from pooled samples of Sick, Farm and Market chickens in Nairobi County, Kenya

Ms. Tino A Deng (✉ tinoayul@gmail.com)

University of Nairobi

Prof. Lilly C Bebor

University of Nairobi

Dr. Mahacla O. Odongo

University of Nairobi

Dr. Gerald M Muchemi

University of Nairobi

Dr. Samuel M Kariuki

Kenya Medical Research Institute

Prof. Peter K. Gathumbi

University of Nairobi

Research Article

Keywords: Antimicrobial resistance, Multi-drug resistance, *E. coli*, Chickens, Kenya

Posted Date: March 29th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1403954/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Antimicrobial resistance (AMR) is an emerging global threat to both human and animal health. This is mainly because the same antimicrobial molecules are used for treatment and prophylaxis in both humans and animals; and about 60% of human pathogens are shared with animals. Thus, a “One health” approach towards combating AMR is critical for the prevention and control of AMR. There is, therefore, need for routine surveillance for AMR in both human and veterinary medicine so as to establish the current status and to formulate strategies on its mitigation. While there are some published data from AMR studies and reviews, data on the prevailing situation, especially in animals, is inadequate. This paper reports on AMR profiles of *E. coli* isolated from chickens in selected parts of Kenya.

Methods: In an effort to establish the antimicrobial resistance profile of bacteria isolated from chicken, A cross-sectional study was carried out in Nairobi County, Kenya. Chickens were purposively selected from three sources: 50 from sick chickens brought to the Poultry clinic at the department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi, for disease diagnosis (post-mortem examination), 50 from a commercial poultry farm in Nairobi, and 72 from a poultry slaughterhouse in Nairobi.

The clinical (sick) cases included broilers, layers, indigenous chickens from various farms, suffering from various disease conditions. Samples from which *E. coli* was isolated, were considered as representative of strains present in other chickens. The commercial farm kept layers under slatted floor (wire mesh) system. Chicken brought to the slaughterhouse were mainly of indigenous type and spent layers, from various parts of Kenya.

Cloacal swabs were taken and the samples placed in Stuart’s transport medium and transported to the microbiology laboratory at the department. Isolation of *E. coli* was done by streak-inoculating swab samples on MacConkey agar (Oxoid Ltd) followed by incubation at 37° C overnight.

Results: *E. coli* was recovered from 54/172 samples (31.4%). The study showed that *E. coli* isolates from the chickens were resistant, at varying levels, to some of the tested antimicrobials; particularly to the ones commonly-used, including: Ampicillin (resistance rate of 85.2%), Tetracycline (66.7%), Co-trimoxazole (57.4%) and Streptomycin (40.7%); low resistances were demonstrated with respect to Nalidixic acid at 24.1%; Chloramphenicol at 14.8% (1 isolate). In contrast, high susceptibilities were observed to Amoxicillin and Gentamycin, each at 96.3%. Six (11.1%) of the isolates were resistant to one antimicrobial (Ampicillin) only, and 5 (9.3%) were susceptible to all the 8 antimicrobials tested, while the rest showed variable resistance to multiple antimicrobials, ranging from 2 to 6.

The low *E. coli* recovery of 31.4% (54/172) was contrary to what was expected since *E. coli* lives as a commensal in both humans and animals and is the most commonly-found bacteria (coprobacteria) in the faeces. However, this less-than-100%-recovery using cloacal swab method has been observed in other studies.

This could be due to intermittent shedding of enterobacteria in feces, so if one does not detect the organism with the cloacal-swab method, it does not mean that the animal is completely free of the organism.

Conclusion, this study has demonstrated carriage of antimicrobial resistant *E. coli* in Kenyan chickens; worst-still is the fact that most of them showed multi-resistances ranging from 2 to 6. Evidence of correalition between antimicrobial usage and development of antibiotic resistant was demonstrated. This information will contribute towards data on current AMR status in bacteria harbored by chickens in Kenya.

Background

Antimicrobials are essential for human health and animal health (www.reactgroup.org), but need to be used cautiously. Livestock (including poultry and fish) health is important for human welfare in two ways: (1) It improves animal welfare, which translates to improved productivity and economic status, thus contribute towards food security and (2) It ensures food safety, since it is estimated that about 60% of bacteria that are pathogenic to humans are from animals/animal products (OIE, 2015), The major problem, with respect to development of antimicrobial resistance, is the fact that same drugs/medicines are used in both humans and animals for treatment or prophylaxis of disease (OIE 2015; GEN 2016, de Souza and Hidalgo 1997; Phillips *et al.*, 2004, Gelband *et al.*, 2015), and a large percentage of bacteria (pathogenic or not) are shared between the two groups. Prudent use of antimicrobials in animals is, therefore, important as it will control the transfer of antimicrobial resistance between animals and humans (Mitema *et al.*, 2001). Indiscriminate usage of antimicrobials, for example, as growth promoters in veterinary medicine (Hart *et al.* 2004; Kimera *et al.*, 2020; Giguère *et al.*, 2013; Martin *et al.*, 2015) contributes directly to emergence and spread of resistance. Indeed, worldwide, it is estimated that 66% of all antimicrobials are used in farm animals, not people; and that much of this use is routine – used to enable farm animals, mostly pigs and poultry, but sometimes also cattle, to be kept in poor conditions where disease spreads easily (Van Boeckel *et al.*, 2015; WHO 2017; Manyi-Loh *et al.*, 2018; Yang *et al.*, 2004). In cases of antimicrobial resistance, the resultant food-borne or animal-acquired illness in humans will be less responsive to treatment with respective antimicrobial drug(s).

Since the fight against antimicrobial resistance is of global multitude (Maron 2016; Perovic and Schultz 2016; Teale and Moulin 2012), it is important for each country to establish its current status, and also carry out continuous routine surveillance in order to harness data for action. In Kenya, as in most developing countries, it is difficult to get a complete picture of the AMR situation, especially in animals, as antimicrobial susceptibility testing is not done routinely in diagnostic laboratories (it is only done on specific requests) and specific researches are scarce. It is, however, appreciated that a number of studies on antimicrobial resistance in animals have been carried out in Kenya, and a number of them have been published (Wanja *et al.*, 2020; Mutua *et al.*, 2017; Kikui *et al.*, 2010; Kutto 2012; Gakuya *et al.*, 2007; Njagi *et al.*, 2004; Bebora *et al.*, 1994;). There are also reviews by Mitema and Kikui (2004) and Kariuki (2011; 2016). The consolidated reports on the situation analysis of AMR in Kenya, by Kariuki (2011; 2016), have covered studies done in humans and animals but require updating, especially with respect to animals. This study has determined extent of antimicrobial resistance in *Escherichia coli*

isolates from pooled samples of three groups of chickens. Chickens were used because they are kept and consumed by many Kenyans and there is also a high tendency of using antimicrobials when the chickens are kept under intensive farming system. *Escherichia coli* was used because it is a common bacterium and also because it is easy to grow and characterize.

Methods

Study design, area and sample chickens

This was a cross-sectional study carried out in Nairobi County, Kenya. It comprised chickens purposively selected from three sources: veterinary poultry clinic, poultry commercial farm and poultry market slaughterhouse. A total of 50 sick chicken that were brought to the Poultry clinic at the department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi, for disease diagnosis (post-mortem examination; regardless of their disease condition), 50 from a commercial farm in Nairobi, and 72 from a slaughterhouse in Nairobi.

The clinical cases included broilers, layers, indigenous chickens from various farms, suffering from various disease conditions (not necessarily caused by *E. coli*) including: septicaemia, pneumonia, coccidiosis, New castle disease, Gumboro disease, fowl pox, leucosis, nutritional deficiency, aflatoxicosis, yolk-sac infection, helminthosis, ectoparasites, trauma (e.g. liver rupture). Like healthy chickens, the clinical cases carry *E. coli* in their guts, as commensals; the isolated *E. coli* were, therefore, taken as representatives of strains present in other chickens in the respective farms. Market birds were mainly of indigenous type and spent layers, brought to the slaughterhouse from various parts of Kenya. The farmed chickens were from one farm which was keeping layers under slatted floor (wire mesh) system.

Sample collection, handling and transport

Cloacal swabs were taken from 50 chickens brought to the clinic during the study period, 50 from commercial poultry farm and 72 market (slaughterhouse) The samples were then placed in Stuart's transport medium and transported to the microbiology laboratory at the department of Veterinary Pathology, Microbiology and Parasitology for bacterial isolation and identification.

Isolation and identification of *E. coli*:

Isolation of *E. coli* was done by streak-inoculating swab samples on MacConkey agar (Oxoid Ltd) followed by incubation at 37° C overnight. Organisms from lactose-fermenting (pink) colonies were phenotyped and confirmed as *E. coli* through Gram-staining, growth on Eosin Methylene Blue agar, and testing for motility and biochemical reactions, including: Indole, Methyl red, Voges Proskauer, Citrate, Urease; interpretation done using the criteria given in Bergey's Manual of systemic bacteriology (Holt *et al.*, 1994).

Antimicrobial susceptibility testing of the *E. coli* isolates;

Antimicrobial susceptibility testing was done by Agar Disk Diffusion method as previously described by Bauer *et al.* (1966) and recommended by the Clinical and Laboratory Standards Institute (CLSI; 2020).

The *E. coli* isolates were tested for susceptibility against 8 antimicrobials, commonly-used for treating bacterial infections in both humans and animals; including: Ampicillin (AMP; 25 ug); Tetracycline (TE; 25 ug), Co-trimoxazole (COT; 25 ug), Streptomycin (S; 10 ug), Nalidixic acid (NA; 30ug), Amoxicillin (AMC; 30 ug), Gentamycin (GEN; 10 ug), Chloramphenicol (C; 30 ug) (Oxoid, Basingstoke, United Kingdom). After incubation at 37° C overnight, the diameters of the growth-inhibition zones around the discs were measured. *E. coli* - ATCC 25922 (WHO, 2003), was used as the reference strain. Guidelines provided by the CLSI (2020).

Results

Escherichia coli isolated from chickens

Escherichia coli organisms were isolated from a total of 54 chickens [prevalence of 31.4% (54/172): 36 from the 50 clinical cases sampled (prevalence of 72%); 11 from the 50 farm chickens sampled (prevalence of 22%) and 7 from the 72 market/slaughtered chickens sampled (prevalence of 9.7%)].

Antimicrobial susceptibility/resistance test results for the 54 *E. coli* isolates

The organisms showed highest resistance to Ampicillin at 85.2%, followed by Tetracycline at 66.7%; Co-trimoxazole at 57.4%; Streptomycin at 40.7%. Low resistances were demonstrated to Nalidixic acid at 24.1%; Chloramphenicol at 14.8% (1 isolate); while high susceptibilities were observed for Amoxicillin and Gentamicin, each at 96.3%. There were 6 (11.1%) isolates that were resistant to one antimicrobial (Ampicillin) only, and 5 (9.3%) that were susceptible to all the 8 antimicrobials tested, while the rest showed variable resistances ranging from 2 to 6 antimicrobials. Antimicrobial susceptibility test results of the 54 *E. coli* isolates are shown in Table 1. Figure 1 gives graphical representation of antimicrobial resistance rates for the test isolates.

Table 1
Antimicrobial susceptibility/resistance patterns of the isolated *E. coli*:
n = 54

Antimicrobial	Susceptible		Resistant	
	Number	Percent	Number	Percent
Ampicillin (Amp)	8	14.8	46	85.2
Tetracycline (TE)	18	33.3	36	66.7
Co-trimoxazole (COT)	23	42.6	31	57.4
Streptomycin (S)	32	59.3	22	40.7
Amoxycillin (AMC)	52	96.3	2	3.7
Gentamycin (GEN)	52	96.3	2	3.7
Chloramphenical (C)	46	85.2	8	14.8
Nalidixic acid (NA)	41	75.9	13	24.1

Multidrug resistance in *E. coli* isolates:

Forty-four out of the 54 (81.5%) *E. coli* isolates showed multidrug resistance (resistant to two or more antimicrobials). Figure 2 presents number of organisms resistant to respective number of antimicrobials; antimicrobial combinations resistant-to are given in Table 2; while Fig. 3 shows the number of times an antimicrobial was involved in cases of multi-drug resistance among the *E. coli* isolates. Ten (22.7%) of the multi-drug-resistant isolates were resistant to 2 antimicrobials; 15 (34.1%) were resistant to 3 antimicrobials; 8 (18.2%) to 4, while 5 (11.4%) each were resistant to 5 and 6 antimicrobials, respectively (Fig. 2). Of the 152 times that the test antimicrobials were included in multi-drug combinations, the antimicrobial included most was Ampicillin at 26.3% (40/151); followed by Tetracycline at 23.7% (36/152); Co-trimoxazole at 20.3% (31/152); Streptomycin at 14.5% (22/152); Nalidixic acid at 7.9% (12/152); Chloramphenical at 5.3% (8/152); Gentamicin at 1.3% (2/152) and lastly Amoxicillin at 0.7% (1/152) (Fig. 3).

Table 2
Multi-drug resistant patterns demonstrated by the test isolates

Number of antimicrobials resistant-to	Number of isolates resistant to respective number of antimicrobials	Resistant antimicrobial combinations
2	10	One had combination of COT-TE Six had combination of TE-AMP One had combination of S-TE One had combination of COT-AMP One had combination of S-AMP
3	15	Four had combination of COT-S-AMP Eight had combination of COT-TE-AMP One had combination of NA-S-TE One had combination of C-TE-AMP One had combination of C-S-AMP
4	8	Five had combination of COT-S-TE-AMP Two had combination of COT-NA-TE-AMP One had combination of NA-S-TE-AMP
5	5	One had combination of COT-NA-GEN-TE-AMP Two had combination of COT-NA-S-TE-AMP Two had combination of COT-C-S-TE-AMP
6	5	Three had combination of COT-C-NA-S-TE-AMP One had combination of COT-C-NA-GEN-TE-AMP One had combination of COT-NA-S-AMC-S-TE-AMP
COT – Co-trimoxazole; TE – Tetracycline; AMP – Ampicillin; S – Streptomycin; NA – Nalidixic acid; C – Chloramphenicol; GEN – Gentamycin; AMC – Amoxicillin		

Discussion

This study was carried out to demonstrate the current antimicrobial resistance level in *E. coli* organisms isolated from chicken cloacae, from selected study sites in Nairobi. There was a low *E. coli* recovery of 31.4% (54/172). This was contrary to what was expected since *E. coli* lives as a commensal in both humans and animals; it is the most commonly-found bacteria (coprobacteria) in the faeces (Buxton and Frazer, 1977). However, this less-than-100%-recovery using cloacal swab method has been observed in other studies. Ibrahim *et al.*, (2019) isolated *E. coli* at 53.4% (269/504); Bebora (1979) isolated the organism from 4 lots of chickens at 51.1% (97/133); 46% (98/176), 66% (66/100) and 88% (22/25). There is documentation on intermittent shedding of enterobacteria in feces has previously been documented (Magwood and Bigland 1962; Brownell *et al.*, 1969; Smith *et al.*, 1972; Brown *et al.*, 1975); Shedding is influenced by stress: muscular fatigue, cold, wetness, limitation of food and water, concurrent infection (Brownell *et al.*, 1969). Working on *Salmonella* Typhimurium, Brownell *et al.*, (1969) found that cloacal excretion of the organisms occurred during the first 5 days of infection, after which the excretion dropped considerably. Williams and Whittemore (1976) had similar findings; they also concluded that cloacal swab method was inadequate for isolation of *Salmonella* Typhimurium. The amount of fecal material in the cloacal swab is much less than in intestinal swab, so there is higher chance of not picking the organism, even though present.

Results of this study showed that *E. coli* isolates from the screened chickens were resistant, though at varying levels, to some of the commonly-used (because they are cheap, hence affordable to the inhabitants of the study area). They included: Ampicillin (resistance rate of 85.2%), Tetracycline (66.7%), Co-trimoxazole (57.4%) and Streptomycin (40.7%) (Table 2). The resistance may have developed as a result of high or indiscriminate usage of antimicrobials in the area; either by the humans or on their animals; it may also be as a result of environmental contamination through human/animal trafficking across the area (through fecal contamination, spitting or other excrements) or through careless disposal of medicines. This trend of resistance has also been reported in other studies (Bebora, 1987; Ombui *et al.*, 2000; Mapeney *et al.*, 2006; Gakuya *et al.*, 2007; Kikui *et al.*, 2007b; Allorechtova *et al.*, 2012). In this study, it was encouraging to find that there were some bacterial strains that were still susceptible to the commonly-used antimicrobials, for example: 5 (9.3%) of the isolates were susceptible to all the 8 antimicrobials tested. High susceptibilities were observed to Amoxicillin and Gentamycin (each at 96.3%), Chloramphenicol (85.2%) and Nalidixic acid (75.9%).

The presence of zoonotic antimicrobial resistant bacteria in dogs (Guardabassi 2004; Allorechtova *et al.*, 2012) and rats (Gakuya *et al.*, 2007); animals that occur widely in human and chicken environment (Stregowski 2017; Cleaveland *et al.* 2006; Blackburn *et al.*, 2014; Lembo *et al.*, 2011; Wareth *et al.*, 2016) - they are everywhere - in human dwellings (especially in informal settlements), in markets, in farms; so, they can easily acquire and disseminate antimicrobial resistant bacteria. Allorechtova *et al.*, 2012 specifically looked-for ESBL-producing *E. coli* strains in Northern Kenya and demonstrated their presence in humans, dogs and, to a lower extent, cats. Comparing genetic profiles of the ESBL-producing *E. coli* isolates, 8 isolates from dogs and 2 isolates from humans gave identical profiles; while a close relationship (> 95% relationship) was found in one human isolate and one cat isolate. This demonstrates spread of resistant bacteria between humans and dogs; some of them were found to be multi-resistant.

Many classes of antimicrobials have been used to treat both humans and livestock (Phillips *et al.*, 2004). They include: β -lactams (Penicillins and Cephalosporins); Sulphonamides with or without Trimethoprim; Tetracyclines; Macrolides, Lincosamides and Streptogramins; and Quinolones including Fluoroquinolones (Bager and Emborg, 2001). Classes most used to treat livestock are: Penicillin derivatives, such as Ampicillin and Cloxacillin; Sulphonamide, e.g. Tylosin, used for treatment of metritis and acute mastitis in cattle, sheep and goats, enteritis, pneumonia, erysipelas, and infectious arthritis in swine (Giguère *et al.*, 2013). Tylosin is also used to treat chronic respiratory disease in chickens. Tetracycline and Co-trimoxazole (containing sulfamethoxazole and trimethoprim) are two most-used antimicrobials for prophylaxis and as growth promoters in livestock rearing, so as to increase productivity (Giguère *et al.*, 2013).

In Kenya the most commonly used medicine for treatment of poultry is about 45 different types with over 62% identified as antimicrobials, which includes Fosbac® (fosfomycin and tylosin), Tylodox® (Tylosin tartrate 100 mg and Doxycycline hyclate 200 mg), Limoxil® (Oxytetracycline), Tylodoxine® (Doxycycline and Tylosin Tartrate), ampicillin, tetracycline, sulphamethoxazole and co-trimoxazole and Tylosine 75® (Tylosin tartrate Eq. 750 000 I.U. and 750 mg Tylosin). The additional remained basic multivitamins, probiotics, and dewormers (Kiambi *et al.*, 2020; Afakye *et al.*, 2021). Therefore, detection of bacteria that are resistant to these antimicrobials is not surprising; meaning that treatments with such antimicrobials are unlikely to be effective. Resistance, particularly to the commonly available antimicrobials, poses a major health concern, as alternative therapeutic choices are either unavailable or too expensive to be affordable for most patients (Kariuki *et al.*, 2010).

Increased use of antimicrobials mainly for prophylaxis and as growth promoters in animals in Kenya is encouraged by the increased demand in milk, meat, eggs, due to increased population and popularization of the products (Manyi-Loh *et al.*, 2018; Van den Bogaard *et al.*, 2001).

Most of the antimicrobials are used in intensively-kept chickens and pigs, while in other livestock, more antimicrobials are used in treatment and prevention of mastitis. The Ministry of Agriculture, Livestock, Fisheries and Irrigation animal census (2017) gives chicken population to be at 48,123,577 (broilers 3,819,515; layers 4,237,188; indigenous 40,067,874). The estimated increases and the high consumption of antimicrobial use in chicken, is correspondingly with reference to given evidence of non-prudent use of antimicrobials in chicken in Kenya. Antimicrobials are commonly purchased deprived of instructions, exposing incorrect practice or purchasing the wrong drug which is self-administered by un-professional i.e. farmers (Kiambi *et al.*, 2021).

The situation is made worse since human doctors and veterinarians tend to use antimicrobials to cover themselves in case of wrong diagnosis or as a cover for any secondary bacterial infection; they use the assurance that: "if it is broad-spectrum, it can shoot better" (Chhorvoin *et al.*, 2016). This, coupled with increased use of antimicrobials in humans, mainly to treat respiratory, enteric and hospital acquired infections (Bururia 2005; Kariuki *et al.*, 2006; 2007; Oundo *et al.*, 2008), and ease of acquiring the antimicrobials over the counter (i.e. purchase without prescriptions) (Ayukekbong *et al.*, 2017) has

contributed to the sky-rocketing levels of antimicrobial resistance experienced today. Most farmers practice mixed animal-raising; that is: they keep many types of animals; there is also close relationship between humans/farmers and their animals; so, resistant bacteria can easily be transferred across the animals and to/from humans.

Eighty-one point five percent (81.5%; 44/54) of the *E. coli* isolates, in this study, showed multidrug resistance; Ten (22.7%) of the multi-drug-resistant isolates were resistant to 2 antimicrobials; 15 (34.1%) were resistant to 3 antimicrobials; 8 (18.2%) to 4, while 5 (11.4%) each were resistant to 5 and 6 antimicrobials, respectively (Fig. 2). Of the 152 times that the test antimicrobials were included in multi-drug combinations, the antimicrobial included most was Ampicillin at 26.3% (40/151); followed by Tetracycline at 23.7% (36/152); Co-trimoxazole at 20.3% (31/152); Streptomycin at 14.5% (22/152); Nalidixic acid at 7.9% (12/152); Chloramphenicol at 5.3% (8/152); Gentamycin at 1.3% (2/152) and lastly Amoxicillin at 0.7% (1/152) (Fig. 3). This further demonstrates the resistance pattern as being towards the cheap-commonly-used antimicrobials; echoing the worldwide worry towards antimicrobial resistance (GEN 2016; Maron 2016; Perovic and Schultz 2016). Multi-drug resistance has been reported by a number of researchers in Kenya; in animals – Beborra (1987), Ombui *et al.* (2000), Mapeney *et al.* (2006), Gakuya *et al.* (2007), Kikuvi *et al.* (2007b), Allorechtova *et al.* (2012), Igizeneza *et al.* (2020), Wanja *et al.* (2020); in environment – Wambugu *et al.* (2015), Kutto (2012); in humans – Kariuki *et al.* (1996; 2006), Bururia (2005), Oundo *et al.* (2008). It has also been reported by many researchers outside Kenya (Van den Bogaard *et al.* 2001; Ryu *et al.* 2012; Adzikey *et al.* 2012; Nys *et al.*, 2004; Kennedy and Collington (2010); Ulstad *et al.*, 2016; GEN 2016).

Conclusion

This study has demonstrated carriage of antimicrobial resistant *E. coli* in Kenyan chickens; worst-still is the fact that most of them showed multi-resistances ranging from 2 to 6 antimicrobials the number could have been even higher if more antimicrobials were tested. Data from this study will thus contribute towards building on current AMR profiles in bacteria harboured by chickens/animals in Kenya and help inform policymakers in their fight against AMR.

Declarations

Data statistic analysis

The statistical analysis was done using R statistical program. Descriptive statistics appropriate hypothesis tests were carried out to establish the association and correlations between antimicrobial resistance and the selected variables.

Availability of data and materials

The data used and analysed in this study are obtainable from the corresponding author on rational demand.

Acknowledgments

We acknowledge all staff of the bacteriology laboratory in the Department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi. Molecular Biology laboratory staff of Center for Microbiology Research, Kenya Medical Research Institute. The German Academic Exchange Service (DAAD) for awarding me a scholarship.

Funding

The authors received no financial funding for this manuscript.

Author Information

Affiliations

Department of Veterinary Pathology, Microbiology and Parasitology, University of Nairobi,. Box 29053-00625, Nairobi, Kenya

Tino A. Deng, Lilly C. Beborra, Mahacla O. Odongo and Peter K. Gatbumbi

Department of Public Health, Pharmacology and Toxicology, University of Nairobi.

P.O. Box 29053-00625, Nairobi, Kenya

Gerald M. Muchemi

Center for Microbiology Research, Kenya Medical Research Institute (KEMRI).

P.O Box 43640–00100, Nairobi, Kenya

Samuel Kariuki

Contributions

TAD, LCB, MOO, SK, GMM and PKG and Conceptualized and study design. TAD, LCB, MOO and SK planned and completed data collection. GMM did the statistical analysis. LCB, TAD and MOO wrote the first draft of the manuscript. TAD, LCB, MOO, GMM, SK and PKG Wrote, reviewed and edited the manuscript. LCB, MOO, PKG, SK and GMM contributed technically and financially towards the completion of the study. All authors have read and agreed to published the manuscript.

Ethics approval

This research was conducted after obtaining ethical approval of research proposal by Biosafety, Animal Use and Ethics Committee (REF: FVM BAUEC/2016/104), Faculty of Veterinary Medicine, University of Nairobi, Kenya. This research was prepared in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for Experiments in Animals.

Corresponding author

Correspondence to Tino A. Deng

Consent for publication

All authors declare consent for publication the research

Conflicts of Interest:

The authors declare no conflict of interest.

References

1. **Adzikey F, Huda N. and Ali G. R (2012):** Prevalence and antibiotic resistance of *Campylobacter*, *Salmonella* and *Listeria monocytogenes* in ducks: A review (Malaysia). *Foodborne Pathogens and Diseases* 9(6):498-505.
2. **Afakye K., Kiambi S., Koka E., Kabali E., Dorado-Garcia A., Amoah A., Kimani T., Adjei B., and Caudel M. A. (2020).** The Impacts of Animal Health Service Providers on Antimicrobial Use Attitudes and Practices: An Examination of Poultry Layer Farmers in Ghana and Kenya. *Antibiotics*, 9(9), 554; <https://doi.org/10.3390/antibiotics9090554>.
3. **Allorechtova K, Cizek D.M, Tausova D, Klimes J, Bebora L.C. and Literak I. (2012):** Dogs of nomadic pastoralists in Northern Kenya are reservoirs of plasmid-mediated cephalosporin- and quinolone-resistant *Escherichia coli*, including pandemic clone B2-O25-ST131.
4. **Ayukekibong J. A, Ntemgwa M. and Atabe A. N. (2017):** The threat of antimicrobial resistance in developing countries: Causes and control strategies. *Antimicrobial Resistance and Infection Control*. 6:47. DOI: 10.1186/s13756-017-0208-x
5. **Bager F. and Emborg H. D. Eds (2001):** DANMAP 2000—Consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, Danish Veterinary Laboratory, Copenhagen, Denmark. ISSN 1600–20.
6. **Bauer A, Kirby W. M, Sherris J. and Turck M. (1966):** Antibiotic Susceptibility Testing by a Standardized Single Disk Method, *American Journal of Clinical Pathology*, 45(4): 493–496.
7. **Bebora LC. (1979):** A study of the occurrence of salmonellosis in some farms and a slaughterhouse in Kenya. MSc thesis, University of Nairobi.
8. **Bebora L.C. (1987):** Fowl typhoid: The disease, immunity and control. PhD thesis, University of Nairobi.
9. **Bebora L.C, Oundo J.O. and Yamamoto H. (1994):** Resistance of *E. coli* strains, recovered from chickens, to various antibiotics used for treatment of humans, with particular attention to trimethoprim-sulphamethoxazole (septrin). *East African Medical Journal* 71(10):624-627.
10. **Blackburn J.K, Skrypnik A, Bagamian K.H, Nikolich M.P, Bezymennyi M. and Skrypnik V. (2014):** Anthrax in a backyard domestic dog in Ukraine: A case report. *Vector Borne and Zoonotic Diseases* 14(8):615-617.
11. **Brown D.D, Ross J.G. and Smith A.F.G. (1975):** Experimental infection of cockerels with *Salmonella* Typhimurium. *Research in Veterinary Sciences*. 18:169.
12. **Brownell J.R, Sadler W.W. and Fanelli M.J. (1969):** Factors influencing the intestinal infection in chickens with *Salmonella* Typhimurium. *Avian Diseases* 13:804.
13. **Bururia J.M. (2005):** Characterisation of multiple drug resistant *Klebsiella* strains isolated in Kenya. MSc thesis, University of Nairobi.
14. **Buxton, A. and Fraser, G. (1977):** Animal Microbiology Black well Scientific Publication volume 1. London, Oxford, UK.
15. **Chhorvoin O. M, Daily F, Vlieghe E, McLaughlin J.C. and McLaws M. (2016):** "If it is a broad spectrum, it can shoot better": inappropriate antibiotic prescribing in Colombia. *Antimicrobial Resistance and Infection Control* 15:58.
16. **Cleaveland S, Meslin E.X. and Breiman R. (2006):** Dogs can play useful role as sentinel hosts for disease. *Nature* 440:605.
17. **CLSI (Clinical and Laboratory Standards Institute) (2020):** Performance standards for antimicrobial susceptibility testing; Eighteenth informational supplement vol. 28 No.1 M100-s18, ISBN1-56238-653-0.
18. **de Souza C. M. and Hidalgo M. P. L. (1997).** The Medical Impact of Antimicrobial Use in Food Animals. Report of a WHO Meeting. Berlin, Germany, 13-17 October 1997. World Health Organization, (October):13–17.

19. **Gakuya F.M, Kyule M.N, Gathura P.B. and Kariuki S.M. (2007):** Antimicrobial resistance of bacterial organisms isolated from rats. *East African Medical Journal* 78(12):646-649.
20. **Gelband H, Miller-Petrie M, Pant S, Gandra G, Levinson J, Barter D, White W. and Laxminarayan R. (2015):** The State of the World's Antibiotics, 2015. Centre for Disease Dynamics, Economics and Policy; Washington, DC, USA.
21. **GEN News Highlight (2016):** Antibiotic resistance grows as last-line drugs fail. Online publication. November 21 2016.
22. **Giguère S, Prescott J. F. and Dowling, P. M. (2013):** Antimicrobial Therapy in Veterinary Medicine, 5th Edition. *Wiley-Blackwell*. ISBN: 978-0-470-96302-9.
23. **Guardabassi L, Schwarz S. and Lloyd D.H. (2004):** Pet animals as reservoirs of antimicrobial-resistant bacteria: Review. *Journal of Antimicrobial Chemotherapy* 54(2):321–332, <https://doi.org/10.1093/jac/dkh332>.
24. **Hart W. S, Heuzenroeder M. W. and Barton, M.D. (2004):** Antimicrobial resistance in *Campylobacter spp.*, *Escherichia coli* and enterococci associated with pigs in Australia. *Journal of Veterinary Medicine Series B: Infectious Diseases and Veterinary Public Health* 51(5): 216–221.
25. **Helmuth R. and Hensel A. (2004):** Towards the Rational Use of Antibiotics: Results of the First International Symposium on the Risk Analysis of Antibiotic Resistance. *Journal of Veterinary Medicine* 51:357–360.
26. **Holt J.G, Krieg N.R, Sneath P.H.A, Staley J.T. and Williams S.T. (1994):** Bergey's manual of determinative bacteriology. William and Wilkins (eds), 9th edition. London. Munich. Sydney. Tokyo 566-570.
27. **Ibrahim R.A, Cryer T.L, Laft S.Q, Basha E, A, Good L. and Tarazi Y.H. (2019):** Identification of *Escherichia coli* from broiler chickens in Jordan, their antimicrobial resistance, gene characterization and the associated risk factors. *BMC Veterinary Research* 15:159 (16 pages) DOI: 10.1186/s12917-019-1901-1.
28. **Igizeneza A, Bebora L. C, Nyaga P. N. and Njagi L. W. (2020):** Antibiotic resistance in bacteria isolated from indigenous slaughter chicken in Nairobi, Kenya. *East African Medical Journal* Vol. 95 No. 10 - published 08.01.2020.
29. **Kariuki S. M, Gilks C, Corkill J, Benea A, Waiyaki P. and Hart C. A. (1996):** Multi-drug resistant, non-typhi salmonellae in Kenya. *Journal of Antimicrobial Chemotherapy* 38(3):425-434.
30. **Kariuki S, Revathi G, Gakuya F, Yamo V, Muyodi J. and Hart A (2002):** Lack of clonal relationship between non-typhi *Salmonella* strains from humans and those from animals living in close contact. *FEMS Immunology Medicine Microbiology* 33: 165-71.
31. **Kariuki S. M. and Revathi G. (2006):** Invasive multidrug-resistant non-typhoidal *Salmonella* infections in Africa: zoonotic or anthroponotic transmission? *Journal of Medical Microbiology* 55:585-591.
32. **Kariuki S. M, Revathi G, Kariuki N, Kiiru J, Mwituria J. and Hart C. A. (2006):** Characterization of community-acquired non-typhoidal *Salmonella* from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. *BMC Microbiology* 2006:101. DOI:10.1186/1471-2180-6-101.
33. **Kariuki S. M, Revathi G, Corkill J, Kiiru J, Mwituria J, Mirza N. and Hart C. A. (2007):** *Escherichia coli* from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams. *Journal of Infection in Developing Countries*, 1(3):257-262.
34. **Kariuki S. M. (2011):** Antibiotic Use and Resistance in Kenya. (August 2011). FAO report.
35. **Kariuki S. M. (2016):** Situation Analysis: Antibiotic Use and Resistance in Kenya, under the Global Antibiotic Resistance Partnership (GARP) in Kenya. FAO report (www.cddep.org/sites/cddep.org/files/.../kenya_full_report_web.pdf).
36. **Kariuki S. Mbae C, Van Puyvelde S, (2020).** High relatedness of invasive multi-drug resistant non-typhoidal *Salmonella* genotypes among patients and asymptomatic carriers in endemic informal settlements in Kenya. *PLoS Neglected Tropical Diseases* 14:e0008440, <https://doi.org/10.1371/journal.pntd.0008440>.
37. **Kennedy K. and Collington P. (2010):** Colonisation with *Escherichia coli* resistant to "critically important" antibiotics: a high risk for international travellers. *European Journal of Clinical Microbiology and Infectious Diseases* 29(12): 1501-1506.
38. **Kikuvi G. M, Schwartz S, Ombui J. N, Mitema E. S. and Kehrenberg C. (2007a):** Streptomycin and Chloramphenicol resistance genes in *Escherichia coli* isolates from cattle, pigs and chicken in Kenya. *Microbial Drug Resistance* 13 (1): 62-68.
39. **Kikuvi G. M, Ombui J. N, Mitema E. S. and Schwartz S. (2007b):** Antimicrobial resistance in *Salmonella* serotypes isolated from slaughter animals in Kenya. *East African Medical Journal* 84(5):233-239.
40. **Kikuvi G. M, Ombui J. N. and Mitema E. S. (2010):** Serotypes and antimicrobial resistance profiles of *Salmonella* isolates from pigs at slaughter in Kenya. *Journal of Infection in Developing Countries* 4(4):243-248.
41. **Kiambi S., Mwanza R., Anima Sirma A., Christine Czerniak C., Kimani T., Kabali E., Dorado-Garcia A., Eckford S., Price C., Gikonyo S., Byarugaba D K., and Caudell M A., (2021).** Understanding Antimicrobial Use Contexts in the Poultry Sector: Challenges for Small-Scale Layer Farms in Kenya. *Antibiotics* 2021, 10, 106. <https://doi.org/10.3390/antibiotics10020106>
42. **Kimera Z. I, Mshana S. E, Rweyemamu M. M, Mboera L. and Matee M. (2020):** Antimicrobial use and resistance in food-producing animals and the environment: an African perspective. *Antimicrobial Resistance and Infection Control* (2020):9-37 <https://doi.org/10.1186/s13756-020-0697-x> .
43. **Kutto E.K. (2012):** Bacteriological contamination of farm and market kale in Nairobi and its environs; pathogenicity and antibiotic sensitivity of isolated salmonellae. MSc thesis UoN pp. 79-83.
44. **Lembo T, Hampson K, Auty H, Beesley C.A, Bessell P, Packer C, Halliday J, Fyumagwa R, Hoare R, Ernest E, Mentzel C, Mlengeya T, Stamey K, Wilkins P.P. and Cleaveland S. (2011):** Serologic surveillance of anthrax in the Serengeti ecosystem, Tanzania 1996-2009. *Emerging Infectious Diseases* 17:387-394.

45. **Magwood S.E. and Bigland C.H. (1962):** Salmonellosis in turkeys: Evaluation of bacteriological and serological evidence of infection. *Canadian Journal of Comparative Medicine* 26:151.
46. **Manyi-Loh C, Mamphweli S, Meyer E, and Okoh A. (2018):** Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. *Molecules* 23(4): 795, DOI:10.3390/molecules23040795.
47. **Mapenay I.M, Kikui G.M, Mitema E.S. and Ombui J. (2006):** Antibiotic Resistance of *Escherichia coli* Isolated from Healthy Food Animals in Kenya. *Kenya Veterinarian* 30(1): 23-27. DOI: 10.4314/kenvet.v30i1.39620.
48. **Maron, D. F. (2016):** Superbug explosion triggers UN General Assembly (UNGA) meeting. Scientific American – On line.
49. **Martin M. J, Thottathil S.E. and Newman T.B. (2015):** Antibiotics Overuse in Animal Agriculture: A Call to Action for Health Care Providers. *American Journal of Public Health*. 105(12):2409–2410, DOI: 10.2105/AJPH.2015.302870.
50. **Mitema E. S, Kikui G. M, Wegener H. C. and Stohr K. (2001):** An Assessment of antimicrobial consumption in food producing animals in Kenya. *Journal of Veterinary Pharmacology and Therapeutics* 24: 385–390.
51. **Mitema E. S. and Kikui G. M. (2004):** Surveillance of the overall use of antimicrobial drugs in humans over a 5-year period (1997-2001) in Kenya. *Journal of Antimicrobial Chemotherapy* 54:966-967..
52. **Mutua J.M, Gitao C.G, Bebora L.C. and Mutua F.K. (2017):** Antimicrobial resistance profiles of bacteria isolated from the nasal cavity of camels in Samburu, Nakuru, and Isiolo counties of Kenya. *Journal of Veterinary Medicine* Volume 2017, Article ID 1216283, 6 pages <https://doi.org/10.1155/2017/1216283>.
53. **Njagi L.W, Mbutia P.G, Bebora L.C, Nyaga P.N, Minga U.M. and Olsen J.E. (2004):** Sensitivity of *Listeria* species recovered from indigenous chickens, to antibiotics and disinfectants. *East African Medical Journal* 81(10):534-537.
54. **Nys S, Okeke N, Kariuki S, Dinant C. J, Driesen C. and Stobberingh E. E. (2004):** Antibiotic resistance of fecal *Escherichia coli* from healthy volunteers from eight developing countries. *Journal of Antimicrobial Chemotherapy* 54(5): 952-955.
55. **Ombui J.N, Kimotho A.M. and Nduhiu J.G. (2000):** Antimicrobial resistance patterns and plasmid profiles of *Staphylococcus aureus* isolated from milk and meat. *East African Medical Journal* 77(9): 463 – 467.
56. **OIE (2015):** Fact sheet on Antimicrobial resistance.
57. **Oundo J. O, Kariuki S. M, Boga H. I, Muli F. W. and Iijima Y. (2008):** High incidence of enteroaggregative *Escherichia coli* among food handlers in three areas in Kenya: A possible transmission route of travellers' diarrhoea. *Journal of Travel Medicine* 15(1):31-38.
58. **Perovic O. and Schultz C. (2016):** Stepwise approach for implementation of antimicrobial resistance surveillance in Africa. *African Journal of Laboratory Medicine* ISSN: (On line), pages 5(3): 482-488.
59. **Phillips I, Casewell M, Cox T, De-Groot B, Friis C, Jones R, Nightingale C, Preston R. and John-Waddell J. (2004):** Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. *Journal of Antimicrobial Chemotherapy* 53(1):28–52, <https://doi.org/10.1093/jac/dkg483>.
60. **Riwu K. H. P, Effendi M. H. and Abdul Rantam F. (2020):** A Review of Extended Spectrum β -Lactamase (ESBL) Producing *Klebsiella pneumoniae* and Multidrug Resistant (MDR) on Companion Animals. *Systemic Reviews in Pharmacy* 11(7):270-277.
61. **Ryu S. H, Park S. G, Chai S. M, Hwang Y. O. and Ham H. J. (2012):** Antimicrobial resistance and resistance genes in *E. coli* strains isolated from commercial fish and seafood. *International Journal of Food Microbiology* 152(1-2):12-18.
62. **Smith P.J, Larkin M. and Brooksbank N.H. (1972):** Bacteriological and serological diagnosis of salmonellosis of fowls. *Research in Veterinary Science*. 13:460.
63. **Stregowski J. R, V.T. (2017):** Living with dogs: The human-canine bond; The connection between you and your dog. Wikipedia – updated 22.4.2017.
64. **Teale C. J. and Moulin G. (2012):** Prudent use guidelines: A review of existing veterinary Guidelines. *Revue scientifique et technique* (International Office of Epizootics) 31(1) : 343-354.
65. **Ulstad C. R, Solheim M, Berg M, Liudbaek M, Dable U. R. and Wester A. L. (2016):** Carriage of ESBL/Amp C – producing or Ciprofloxacin non-susceptible *Escherichia coli* and *Klebsiella* spp in healthy people in Norway. *Antimicrobial Resistance and Infection Control* 5:57.
66. **UNGA-United Nations General Assembly (2016):** UN meeting tackles the fundamental threats of antibiotic resistant superbugs.
67. **Van Boeckel T.P, Brower C, Gilbert M, Grenfell B.T, Levin S.A, Timothy P.R, Teillant A. and Laxminarayan R. (2015):** Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences (PNAS) of United States of America 112:5649–5654.
68. **Van den Bogaard A. E., London N, Driessen C. and Stobberingh E. E. (2001):** Antibiotic resistance of fecal *E. coli* in poultry, poultry farmers and poultry slaughterers. *Journal of Antimicrobial Chemotherapy* 47(6):763-771.
69. **Wambugu P, Habtu M, Impwi P, Matiru V. and Kiiru J. (2015):** Antimicrobial susceptibility profiles among *Escherichia coli* strains isolated from Athi River water in Machakos County, Kenya. *Advances in Microbiology* 5:711-719.
70. **Wanja D.W, Mbutia P.G, Waruiru R.M, Bebora L.C, Ngowi H.A. and Nyaga P.N. (2020):** Antibiotic and Disinfectant Susceptibility Patterns of Bacteria Isolated from Farmed Fish in Kirinyaga County, Kenya. *International Journal of Microbiology* Volume 2020, Article ID 8897338, 8 pages <https://doi.org/10.1155/2020/8897338>.
71. **Wareth G, Melzer F, El-Diasty M, Schmoock G, Elbauomy E, Abdel-Hamid N, Sayour A. and Neubauer H. (2016):** Isolation of *Brucella abortus* from a dog and a cat confirms their biological role in re-emergence and dissemination of bovine brucellosis in dairy farms. *Transboundary Emerging Diseases* 64(5): e27-e30.

72. WHO (2003): Implementation workshop on the WHO global strategy for containment of antimicrobial resistance. Geneva: World Health Organization.
73. WHO (2014): Antimicrobial resistance: global report on surveillance 2014. Geneva: World Health Organization; 2014.
74. WHO (2015a): Global Action Plan on Antimicrobial Resistance.
75. WHO (2015b). Global Antimicrobial Resistance Surveillance System (GLASS) manual for early Implementation.
76. WHO (2017): Stop using antibiotics in healthy animals to prevent the spread of antibiotic resistance. News release, Geneva. Doi:10.1111/tbed.12335.
77. Williams J.E. and Whittemore A.D. (1976): Comparison of six methods of detecting *Salmonella* Typhimurium infection of chickens. *Avian Diseases* 20:728.
78. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World.
79. World Health Organization Technical Report Series (2016): WHO Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection Geneva International Conference, Centre Report of a WHO Expert Consultation Geneva WHO/HIV/(2016).01.
80. Yang H, Chen S, White D. G, Zhao S, Mcdermott P, Walker R. and Meng J. (2004): Characterization of Multiple-Antimicrobial-Resistant *Escherichia coli* Isolates from Diseased Chickens and Swine in China. *Journal of Clinical Microbiology*, 42(8), 3483–3489. <https://doi.org/10.1128/JCM.42.8.3483>

Figures




Figure 1
Graph showing resistance rates (%) per antimicrobial. From left to right: Ampicillin, Tetracycline, Co-trimoxazole, Streptomycin, Amoxicillin, Gentamycin, Chloramphenicol, Nalidixic acid, respectively




Figure 2

Number of *E. coli* isolates multi-resistant to respective number of antimicrobials From left to right: 2, 3, 4, 5, 6 antimicrobials




Figure 3

Number of times an antimicrobial was involved in cases of multi-drug resistance among the *E. coli* isolates. From left to right: Ampicillin, Tetracycline, Co-trimoxazole, Sreptomycin, Amoxycillin, Gentamycin, Chloramphenicol, Nalidixic acid, respectively